Fig. 1: The impact of epigenetic modifier gene mutations on the outcome of TKI discontinuation. | Blood Cancer Journal

Fig. 1: The impact of epigenetic modifier gene mutations on the outcome of TKI discontinuation.

From: Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation

Fig. 1

Stacked columns comparing the prevalence of mutations in a cancer-associated genes and b epigenetic modifier genes between relapse and TFR patient groups (n = 47, 30 relapse and 17 TFR patients). Cancer-associated mutations were identified in 10/30 relapse patients compared to 2/17 TFR patients. Epigenetic modifier gene mutations were identified in 8/30 relapse patient compared to 1/17 TFR patients. The list of the identified mutations is provided in Table 1. Survival curves comparing the relapse-free survival rates of patients (n = 47) classified according to c the presence of epigenetic modifier gene mutations using log-rank test, d combinations of epigenetic modifier mutations and duration of TKI treatment prior to stop using stratified log-rank test. Scatter plots showing e the sensitivity of K562-KDM6A-KO cells to NK cells (expanded from freshly isolated NK cells from two different healthy donors’ buffy coats) induced cytotoxicity compared to control K562 cells, f Expression of CD107a degranulation marker on CD56 + NK cells cocultured with either K562_control or K562_KDM6A_KO cells (clones #1 and #2). (*) p < 0.05, Chi-square test.

Back to article page